Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone presented as a tablet for oral use. It treats infections caused by Gram‑positive bacteria, including MRSA and VRE, in adult patients.

GNH USA supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid Krka is an oxazolidinone antibiotic indicated for serious Gram‑positive bacterial infections. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides effective bacterial clearance in adult patients. - Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative oral therapy for resistant strains. - Community‑acquired pneumonia: treats pneumonia caused by susceptible Gram‑positive organisms. - Skin and soft tissue infections caused by Gram‑positive bacteria: resolves infection and promotes healing.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal discomfort. - Diarrhea: loose stools, usually mild. - Headache: occasional tension‑type headache. - Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Peripheral neuropathy: sensory changes that may be irreversible. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance needing urgent care.

Before prescribing Linezolid Krka, consider the following safety measures. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution and observe liver enzymes. - Concomitant serotonergic agents: assess risk of serotonin syndrome. - Prolonged therapy: regularly monitor complete blood counts. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Linezolid Krka can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): increased risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): may precipitate serotonin syndrome. - Rifampicin: reduces linezolid plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Phenytoin: may lower linezolid levels, reducing therapeutic effect. - Erythromycin: can raise linezolid concentrations, increasing toxicity risk.